Skip to main content
SpringerLink
Log in

Early Onset Schizophrenia

  • Chapter
  • First Online:
Handbook of Schizophrenia Spectrum Disorders, Volume II

Abstract

Early onset schizophrenia (EOS) describes onset of the first episode of psychosis before age 18 years. Such an earlier onset of symptoms is often associated with a severe and chronic course of the illness, a poorer prognosis and a potentially significant negative impact on recovery and rehabilitation. A recent emphasis on early intervention by utilizing the advances in neurobiological and psychosocial domains along with psychopharmacological effectiveness research in managing this chronic psychotic disorder is paving the way for a more rigorous study of this chronic disabling disorder. This chapter reviews recent literature on diagnostic assessment and management of schizophrenia when it strikes during formative years, and provides future directions for further research in the area.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AOS:

Adult onset schizophrenia

APRS:

Attenuated psychotic symptoms syndrome

BPRS:

Brief psychiatric rating scale

CGI:

Clinical global impression

CHR:

Clinical high risk

CNV:

Copy-number variation

COS:

Childhood onset schizophrenia

DLPFC:

Dorsolateral prefrontal cortex

DSM-IV TR:

Diagnostic and statistical manual of mental disorders, Fourth edition, Text revision

EPSE:

Extrapyramidal side effects

FDA:

Food and Drug Administration

FEP:

First episode of psychosis

ICD-10:

International statistical classification of diseases and related health problems 10th revision

MRI:

Magnetic resonance imaging

NIMH:

National Institute of Mental Health

PANNS:

Positive and negative syndrome scale

PRS:

Psychosis risk syndrome

TSH:

Thyroid stimulating hormone

UHR:

Ultra high risk

VEOS:

Very early onset schizophrenia

References

  1. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th edn, Text Revision. American Psychiatric Association, Washington, DC

    Google Scholar 

  2. Young CM, Findling RL (2004) Pharmacologic treatment of adolescent and child schizophrenia. Expert Rev Neurother 4(1):53–60

    Article  CAS  PubMed  Google Scholar 

  3. Armenteros JL, Davies M (2006) Antipsychotics in early onset Schizophrenia: systematic review and meta-analysis. Eur Child Adolesc Psychiatry 15(3):141–148

    Article  PubMed  Google Scholar 

  4. Madaan V, Dvir Y, Wilson DR (2008) Child and adolescent schizophrenia: pharmacological approaches. Expert Opin Pharmacother 9:2053–2068

    Article  CAS  PubMed  Google Scholar 

  5. Asarnow JR (2005) Childhood-onset schizotypal disorder: a follow-up study an dcomparison with childhood-onset schizophrenia. J Child Adolesc Psychopharmacol 15:395–402

    Article  PubMed  Google Scholar 

  6. Nicolson R, Rapoport JL (1999) Childhood-onset schizophrenia: rare but worth studying. Biol Psychiatry 46(10):1418–1428

    Article  CAS  PubMed  Google Scholar 

  7. Remschmidt H, Martin M, Fleischhaker C et al (2007) Forty-two-years later: the outcome of childhood-onset schizophrenia. J Neural Transm 114(4):505–512

    Article  CAS  PubMed  Google Scholar 

  8. Salokangas RK, McGlashan TH (2008) Early detection and intervention of psychosis. A review. Nord J Psychiatry 62(2):92–105

    Article  PubMed  Google Scholar 

  9. http://apps.who.int/classifications/apps/icd/icd10online/. Accessed August 1, 2010

  10. Masi G, Mucci M, Pari C (2006) Children with schizophrenia: clinical picture and pharmacological treatment. CNS Drugs 20(10):841–866

    Article  CAS  PubMed  Google Scholar 

  11. Practice Parameter for the Assessment and Treatment of Children and Adolescents with schizophrenia. http://www.aacap.org/galleries/PracticeParameters/JAACAP%20Schizophrenia%202001.pdf. Accessed on 7/19/10

  12. Yung AR, Mcgorry PD (1996) The prodromal phase of first episode psychosis: past and current conceptualizations. Schizophr Bull 22:353–370

    CAS  PubMed  Google Scholar 

  13. Klosterkötter J, Hellmich M, Steinmeyer EM, Schultze-Lutter F (2001) Diagnosing schizophrenia in the initial prodromal phase. Arch Gen Psychiatry 58:158–164

    Article  PubMed  Google Scholar 

  14. Yung AR, Mcgorry PD (2007) Prediction of psychosis: setting the stage. Br J Psychiatry 191(Suppl 51):s1–s8

    Article  Google Scholar 

  15. http://www.dsm5.org/ProposedRevisions/Pages/proposedrevision.aspx?rid=412. Accessed on 7/20/10

  16. Yung AR, Nelson B, Stanford C, Simmons MB, Cosgrave EM, Killackey E, Phillips LJ, Bechdolf A, Buckby J, McGorry PD (2008) Validation of “prodromal” criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr Res 105(1–3):10–17

    Article  PubMed  Google Scholar 

  17. De Koning MB, Bloemen OJ, van Amelsvoort TA et al (2009) Early intervention in patients at ultra high risk of psychosis: benefits and risks. Acta Psychiatr Scand 119(6):426–442

    Article  PubMed  Google Scholar 

  18. Yung AR, Nelson B, Thompson AD, Wood SJ (2010) Should a “Risk Syndrome for Psychosis” be included in the DSMV? Schizophr Res 120(1–3):7–15

    Article  PubMed  Google Scholar 

  19. Correll CU, Hauser M, Auther AM, Cornblatt BA (2010) Research in people with psychosis risk syndrome: a review of the current evidence and future directions. J Child Psychol Psychiatry 51(4):390–431, Epub 2010 Feb 26

    Article  PubMed  Google Scholar 

  20. Bettes BA, Walker E (1987) Positive and negative symptoms in psychotic and other psychiatrically disturbed children. J Child Psychol Psychiatry 28(4):555–568

    Article  CAS  PubMed  Google Scholar 

  21. McClellan J, McCurry C, Speltz ML et al (2002) Symptom factors in early-onset psychotic disorders. J Am Acad Child Adolesc Psychiatry 41:791–798

    Article  PubMed  Google Scholar 

  22. McClellan J, Breiger D, McCurry C et al (2003) Premorbid functioning in early-onset psychotic disorders. J Am Acad Child Adolesc Psychiatry 42:666–672

    Article  PubMed  Google Scholar 

  23. Hooper SR, Giuliano AJ, Youngstrom EA et al (2010) Neurocognition in early-onset schizophrenia and schizoaffective disorders. J Am Acad Child Adolesc Psychiatry 49(1):52–60

    PubMed  Google Scholar 

  24. Rapoport JL, Addington AM, Frangou S (2005) The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 10:434–449

    Article  CAS  PubMed  Google Scholar 

  25. Shaw P, Gogtay N, Rapoport J (2010) Childhood psychiatric disorders as anomalies in neurodevelopmental trajectories. Hum Brain Mapp 31(6):917–925

    Article  PubMed  Google Scholar 

  26. Addington AM, Rapoport JL (2009) The genetics of childhood-onset schizophrenia: when madness strikes the prepubescent. Curr Psychiatry Rep 11(2):156–161

    Article  PubMed  Google Scholar 

  27. Gothelf D, Feinstein C, Thompson T et al (2007) Risk factors for the emergence of psychotic disorders in adolescents with 22q11.2 deletion syndrome. Am J Psychiatry 164(4):663–669

    Article  PubMed  Google Scholar 

  28. Bennett MR (2009) Synapse formation and regression in the cortex during adolescence and in schizophrenia. Med J Aust 190(Suppl 4):S14–6

    Google Scholar 

  29. Walsh T, McClellan JM, McCarthy SE et al (2008) Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320:539–543

    Article  CAS  PubMed  Google Scholar 

  30. Moore TH, Zammit S, Lingford-Hughes A et al (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370(9584):319–328

    Article  PubMed  Google Scholar 

  31. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108969.htm Accessed on 7/20/10

  32. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021436s027lbl.pdf

  33. http://www.medscape.com/viewarticle/713484 Accessed on 7/20/10

  34. http://www.astrazeneca-us.com/?itemId=7659483 Accessed on 7/20/10

  35. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm196973.htm accessed on 7/20/10

  36. Haas M, Unis AS, Copenhaver M et al Efficacy and safety of risperidone in adolescents with schizophrenia [poster]. Presented at 160th annual meeting of the American Psychiatric Association, San Diego, CA, 19–24 May 2007

    Google Scholar 

  37. Pandina G, Kushner S, Singer J et al Comparison of two risperidone dose ranges in adolescents with schizophrenia [poster]. Presented at the 54th annual meeting of the American Academy of Child and Adolescent Psychiatry, Boston, MA, 23–28 October 2007

    Google Scholar 

  38. Madaan V (2009) Risperidone: a review of efficacy studies in adolescents with schizophrenia. Drugs Today (Barc) 45(1):55–62

    Article  Google Scholar 

  39. Findling RL, Robb A, Nyilas M et al (2008) A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 165(11):1432–1441

    Article  PubMed  Google Scholar 

  40. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM177119.pdf Accessed on 7/20/10

  41. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020639s045s046lbl.pdf Accessed on 7/20/10

  42. Mattai AK, Hill JL, Lenroot RK (2010) Treatment of early-onset schizophrenia. Curr Opin Psychiatry. 23(4):304–310

    Article  PubMed  Google Scholar 

  43. Correll CU, Manu P, Olshanskiy V et al (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302(16):1765–1773

    Article  CAS  PubMed  Google Scholar 

  44. Correll CU (2009) Multiple antipsychotic use associated with metabolic and cardiovascular adverse events in children and adolescents. Evid Based Ment Health 12(3):93

    Article  PubMed  Google Scholar 

  45. Morrato EH, Nicol GE, Maahs D et al (2010) Metabolic screening in children receiving antipsychotic drug treatment. Arch Pediatr Adolesc Med 164(4):344–351

    PubMed  Google Scholar 

  46. Sikich L, Frazier JA, McClellan J et al (2008) Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165(11):1420–1431

    Article  PubMed  Google Scholar 

  47. Findling RL, Johnson JL, McClellan J et al (2010) Double-blind maintenance safety and effectiveness findings from the treatment of early-onset schizophrenia spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry 49(6):583–594

    PubMed  Google Scholar 

  48. Sporn AL, Vermani A, Greenstein DK et al (2007) Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry 46(10):1349–1356

    Article  PubMed  Google Scholar 

  49. Kumra S, Oberstar JV, Sikich L et al (2008) Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 34(1):60–71

    Article  PubMed  Google Scholar 

  50. Gerbino-Rosen G, Roofeh D, Tompkins DA et al (2006) Hematological adverse events in clozapine-treated children and adolescents. J Am Acad Child Adolesc Psychiatry 44:1024–1103

    Article  Google Scholar 

  51. Eack SM, Greenwald DP, Hogarty SS et al (2009) Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial. Psychiatr Serv 60(11):1468–1476

    Article  PubMed  Google Scholar 

  52. Townsend L, Findling RL (2010) Modifying the risk of atypical antipsychotics in the treatment of juvenile-onset schizophrenia. Expert Opin Pharmacother 11(2):195–205

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Child and Family Psychiatry, Charlottesville, VA, 22908, USA

    Vishal Madaan (Assistant Professor in Psychiatry and Neurobehavioral Sciences)

  2. Department of Psychiatry, University of Massachusetts Medical School, Worcester, MA, USA

    Yael Dvir

  3. Department of Psychiatry, Creighton University Medical Center, Omaha, NE, USA

    Durga Prasad Bestha & Daniel R. Wilson

Authors
  1. Vishal Madaan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yael Dvir
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Durga Prasad Bestha
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Daniel R. Wilson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vishal Madaan .

Editor information

Editors and Affiliations

  1. , Rappaport Faculty of Medicine, Technion - Israel Institute of Technolog, Haifa, Israel

    Michael Ritsner

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media B.V.

About this chapter

Cite this chapter

Madaan, V., Dvir, Y., Bestha, D.P., Wilson, D.R. (2011). Early Onset Schizophrenia. In: Ritsner, M. (eds) Handbook of Schizophrenia Spectrum Disorders, Volume II. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-0831-0_8

Download citation

Publish with us

Policies and ethics

Search

Navigation